Clinical Trials Browser

Interventional × Refractory or Recurrent Solid Tumors, Excluding CNS Tumors × Axitinib × Clear all

NCT02164838 2018-01-29

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Refractory or Recurrent Solid Tumors, Excluding CNS Tumors